| Year |
Citation |
Score |
| 2022 |
Berrou J, Dupont M, Djamai H, Adicéam E, Parietti V, Kaci A, Clappier E, Cayuela JM, Baruchel A, Paublant F, Prudent R, Ghysdael J, Gardin C, Dombret H, Braun T. Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive () Acute Lymphoblastic Leukemia (ALL). Journal of Clinical Medicine. 11. PMID 36431240 DOI: 10.3390/jcm11226761 |
0.381 |
|
| 2022 |
Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, ... ... Braun T, et al. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia. PMID 35474100 DOI: 10.1038/s41375-022-01573-6 |
0.324 |
|
| 2021 |
Djamai H, Berrou J, Dupont M, Coudé MM, Delord M, Clappier E, Marceau-Renaut A, Kaci A, Raffoux E, Itzykson R, Berthier C, Wu HC, Hleihel R, Bazarbachi A, de Thé H, ... ... Braun T, et al. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines. 9. PMID 34829934 DOI: 10.3390/biomedicines9111704 |
0.368 |
|
| 2021 |
Sevin M, Debeurme F, Laplane L, Badel S, Morabito M, Newman HL, Torres-Martin M, Yang Q, Badaoui B, Wagner-Ballon O, Saada V, Selimoglu-Buet D, Kraus-Berthier L, Banquet S, Derreal A, ... ... Braun T, et al. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood. PMID 33690800 DOI: 10.1182/blood.2020008729 |
0.453 |
|
| 2020 |
Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Leukemia Research. 100: 106490. PMID 33373830 DOI: 10.1016/j.leukres.2020.106490 |
0.361 |
|
| 2020 |
Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances. 4: 1942-1949. PMID 32380535 DOI: 10.1182/Bloodadvances.2019001349 |
0.374 |
|
| 2020 |
Habault J, Kaci A, Pasquereau-Kotula E, Fraser C, Chomienne C, Dombret H, Braun T, Pla M, Poyet JL. Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53. Oncoimmunology. 9: 1728871. PMID 32158621 DOI: 10.1080/2162402X.2020.1728871 |
0.345 |
|
| 2020 |
Kim R, Boissel N, Touzart A, Leguay T, Thonier F, Thomas X, Raffoux E, Huguet F, Villarese P, Fourrage C, Passini L, Hunault M, Lepretre S, Chevallier P, Braun T, et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia. PMID 31992840 DOI: 10.1038/S41375-019-0685-4 |
0.321 |
|
| 2019 |
Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, ... ... Braun T, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Advances. 3: 4238-4251. PMID 31869411 DOI: 10.1182/Bloodadvances.2019000647 |
0.394 |
|
| 2019 |
Massé A, Roulin L, Pasanisi J, Penneroux J, Gachet S, Delord M, Ali A, Alberdi A, Berrou J, Passet M, Hernandez L, Quentin S, Gardin C, Raffoux E, Adès L, ... Braun T, et al. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias. Leukemia Research. 87: 106269. PMID 31751766 DOI: 10.1016/J.Leukres.2019.106269 |
0.401 |
|
| 2019 |
Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, et al. Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements. Blood. PMID 31434701 DOI: 10.1182/Blood.2019001244 |
0.313 |
|
| 2019 |
Kaci A, Adiceam E, Dupont M, Garrido M, Berrou J, Djamai H, Baruchel A, Burbridge M, Gardin C, Dombret H, Braun T. Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL) Blood. 134: 2631-2631. DOI: 10.1182/Blood-2019-125641 |
0.434 |
|
| 2019 |
Braun T, Berrou J, Djamai H, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H. Abstract 341: Synergy of FLT3 inhibitors and a small molecule inhibitor of LIM kinase1/2 in FLT3-ITD positive acute myeloblastic leukemia (AML) Cancer Research. 79: 341-341. DOI: 10.1158/1538-7445.Sabcs18-341 |
0.459 |
|
| 2018 |
Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P. A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM). Haematologica. PMID 30381302 DOI: 10.3324/Haematol.2018.203885 |
0.344 |
|
| 2018 |
Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, et al. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research. 71: 67-74. PMID 30025278 DOI: 10.1016/J.Leukres.2018.05.007 |
0.391 |
|
| 2018 |
Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, ... ... Braun T, et al. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. British Journal of Haematology. PMID 30004110 DOI: 10.1111/Bjh.15490 |
0.341 |
|
| 2018 |
Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. Ebiomedicine. PMID 29728305 DOI: 10.1016/J.Ebiom.2018.04.018 |
0.354 |
|
| 2018 |
Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, et al. Nationwide Survey on the Use of Horse Antithymocyte Globulins (ATGAM) in Patients with Acquired Aplastic Anemia: A Report on Behalf of the French Reference Center for Aplastic Anemia. American Journal of Hematology. PMID 29377260 DOI: 10.1002/Ajh.25050 |
0.324 |
|
| 2018 |
Vidal V, Hamri L, Marceau-Renaut A, Fontbrune FSD, Eclache V, Osman N, Papoular B, Lusina D, Brechignac S, Latour RPD, Preudhomme C, Gardin C, Braun T. A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML) Blood. 132: 4007-4007. DOI: 10.1182/Blood-2018-99-117237 |
0.344 |
|
| 2018 |
Braun T, Berrou J, Prudent R, Djamai H, Dupont M, Kaci A, Adiceam E, Paublant F, Baruchel A, Ghysdael J, Gardin C, Dombret H. Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blood. 132: 2705-2705. DOI: 10.1182/Blood-2018-99-115933 |
0.431 |
|
| 2018 |
Ades L, Guerci A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Bouabdallah K, Braun T, Beyne-Rauzy O, et al. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial Blood. 132: 467-467. DOI: 10.1182/Blood-2018-99-111756 |
0.348 |
|
| 2018 |
Itzykson R, Fournier E, Braun T, Berthon C, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Duployez N, Micol J, Ades L, Marolleau J, Malfuson JV, Gastaud L, Raffoux E, et al. Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial Blood. 132: 993-993. DOI: 10.1182/Blood-2018-99-111144 |
0.341 |
|
| 2018 |
Braun T, Coudé M, Berrou J, Djamai H, Dupont M, Kaci A, Delord M, Itzykson R, Raffoux E, Berthier C, Baruchel A, Gardin C, Dombret H. Abstract 803: Bromodomain and extra-terminal BET inhibitors induce TP53 independent apoptosis, maturation and oncoprotein degradation in NPM1 mutated acute myeloid leukemia Cancer Research. 78: 803-803. DOI: 10.1158/1538-7445.Am2018-803 |
0.473 |
|
| 2017 |
Braun T, Gardin C. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). Expert Opinion On Investigational Drugs. PMID 28541716 DOI: 10.1080/13543784.2017.1335711 |
0.359 |
|
| 2017 |
Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. PMID 28514758 DOI: 10.18632/Oncotarget.17482 |
0.412 |
|
| 2017 |
Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, ... ... Braun T, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 185-193. PMID 28056203 DOI: 10.1200/Jco.2016.67.1875 |
0.391 |
|
| 2017 |
Itzykson R, Lambert J, Barbieri D, Gruson B, Thepot S, Braun T, Vey N, Delaunay J, Legros L, Lejeune J, Sapena R, Droin N, Porteu F, Solary E, Fenaux P. A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia Blood. 130: 4266-4266. DOI: 10.1182/Blood.V130.Suppl_1.4266.4266 |
0.343 |
|
| 2017 |
Duchmann M, Yalniz F, Sanna A, Sallman DA, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Ades L, Fontenay M, Rampal RK, Padron E, Droin N, et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients Blood. 130: 159-159. DOI: 10.1182/Blood.V130.Suppl_1.159.159 |
0.347 |
|
| 2016 |
Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies. British Journal of Haematology. PMID 27977052 DOI: 10.1111/Bjh.14427 |
0.302 |
|
| 2016 |
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. The New England Journal of Medicine. 375: 1044-1053. PMID 27626518 DOI: 10.1056/Nejmoa1605085 |
0.319 |
|
| 2016 |
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, et al. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget. 7: 85573-85583. PMID 27458168 DOI: 10.18632/Oncotarget.10764 |
0.367 |
|
| 2016 |
Fraison JB, Mekinian A, Grignano E, Kahn JE, Arlet JB, Decaux O, Denis G, Buchdahl AL, Omouri M, Maigne G, Aouba A, Leon N, Berthier S, Liozon E, Park S, ... ... Braun T, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research. 43: 13-17. PMID 26922775 DOI: 10.1016/J.Leukres.2016.02.005 |
0.317 |
|
| 2016 |
Michallet M, Sobh M, Deloire A, Raffoux E, Botton Sd, Caillot D, Reman O, Girault S, Berthon C, Huguet F, Lepretre S, Leguay T, Castaigne S, Royer B, Pautas C, ... ... Braun T, et al. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group Blood. 128: 3696-3696. DOI: 10.1182/Blood.V128.22.3696.3696 |
0.301 |
|
| 2015 |
Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 20: 1666-7. PMID 26400497 DOI: 10.1007/S10495-015-1154-9 |
0.798 |
|
| 2015 |
Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 6: 17698-712. PMID 25989842 DOI: 10.18632/Oncotarget.4131 |
0.422 |
|
| 2015 |
Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 125: 3618-26. PMID 25852055 DOI: 10.1182/Blood-2015-01-620781 |
0.321 |
|
| 2015 |
Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, et al. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. Cancer. 121: 2393-9. PMID 25845577 DOI: 10.1002/Cncr.29389 |
0.317 |
|
| 2015 |
Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research. 39: 501-4. PMID 25735917 DOI: 10.1016/J.Leukres.2015.02.004 |
0.379 |
|
| 2015 |
Poret E, Vidal C, Desbrosses Y, Delettre FA, Pagadoy M, Pugin A, Benazet L, Leroux F, Robert E, Binda D, Biichle S, Roggy A, Philippe L, Gruson B, Gac A, ... ... Braun T, et al. How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network Blood. 126: 456-456. DOI: 10.1182/Blood.V126.23.456.456 |
0.367 |
|
| 2015 |
Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N. A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study Blood. 126: 2900-2900. DOI: 10.1182/Blood.V126.23.2900.2900 |
0.349 |
|
| 2015 |
Duchmann M, Braun T, Platzbecker U, Adès L, Sébert M, Dreyfus F, Park S, Vey N, Rauzy OB, Botton SD, Micol J, Berthon C, Guieze R, Bastie JM, Solary É, et al. Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA) Blood. 126: 2893-2893. DOI: 10.1182/Blood.V126.23.2893.2893 |
0.348 |
|
| 2015 |
Bigenwald C, Harel S, Chevillon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Lionel A, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P. Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related Blood. 126: 2886-2886. DOI: 10.1182/Blood.V126.23.2886.2886 |
0.351 |
|
| 2015 |
Sebert M, Stamatoullas A, Braun T, Delaunay J, de Renzis B, Jeddi R, Meddeb B, Hunault Berger M, Samey B, Chermat F, Chevret S, Chaffaut C, Fenaux P, Ades L. Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM) Blood. 126: 2884-2884. DOI: 10.1182/Blood.V126.23.2884.2884 |
0.359 |
|
| 2015 |
Drevon L, Marceau A, Eclache V, Raynaud SD, Richez V, Berkaoui I, Maarek O, Cuccuini W, Lusina D, Berthon C, Dimicoli-Salazar S, Bidet A, Vial J, Park S, Stamatoullas A, ... ... Braun T, et al. MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM Blood. 126: 2881-2881. DOI: 10.1182/Blood.V126.23.2881.2881 |
0.35 |
|
| 2015 |
Duchmann M, Braun T, Kosmider O, Renneville A, Platzbecker U, Ades L, Sebert M, Dreyfus F, Park S, Vey N, Beyne Rauzy O, De Botton S, Micol J, Guieze R, Bastie JM, et al. A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM Blood. 126: 2872-2872. DOI: 10.1182/Blood.V126.23.2872.2872 |
0.35 |
|
| 2015 |
Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Samey B, Desseaux K, Chevret S, Fenaux P. A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM) Blood. 126: 2869-2869. DOI: 10.1182/Blood.V126.23.2869.2869 |
0.347 |
|
| 2015 |
Roulin L, Ali A, Masse A, Coudé M, Bluteau D, Braun T, Berrou J, Bluteau O, Delord M, Riveiro ME, Herait PE, Soulier J, Baruchel A, Gardin C, Dombret H, et al. Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells Blood. 126: 2588-2588. DOI: 10.1182/Blood.V126.23.2588.2588 |
0.405 |
|
| 2015 |
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Braun T, Marolleau J, Chalandon Y, et al. Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study Blood. 126: 1-1. DOI: 10.1182/Blood.V126.23.1.1 |
0.357 |
|
| 2015 |
Braun T, Debache A, Roudot H, Lusina D, Thépot S, Eclache V, Martin A, Soret J, Bréchignac S, Kelaidi C, Adès L, Fenaux P, Gardin C. 205 A SINGLE CENTER REPORT OF THERAPEUTIC STRATEGIES IN PATIENTS WITH ATYPICAL CML (ACML) AND UNCLASSIFIED MDS/MPN (MDS/MPN-U) Leukemia Research. 39: S102. DOI: 10.1016/S0145-2126(15)30206-X |
0.3 |
|
| 2015 |
Ades L, Renneville A, Marceau A, Sebert M, Braun T, Nibourel O, Preudhomme C, Fenaux P. 142 Molecular Prognostic Factors In Higher Risk Mds Receiving First Line Azacytidine (Aza) Leukemia Research. 39. DOI: 10.1016/S0145-2126(15)30143-0 |
0.311 |
|
| 2015 |
Cluzeau T, Vidal V, Ginet C, Karsenti J, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga A, Dombret H, Rorhlich P, Ades L, Chomienne C, et al. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML Leukemia Research. 39: S23. DOI: 10.1016/S0145-2126(15)30051-5 |
0.352 |
|
| 2014 |
Mirouse A, Virone A, Gobert D, Soussan M, Braun T, Ziol M, Gardin C, Fenaux P, Mekinian A, Fain O. Aseptic muscular abscesses associated with myelodysplastic syndrome. European Journal of Dermatology : Ejd. 24: 696-7. PMID 25333797 DOI: 10.1684/Ejd.2014.2435 |
0.315 |
|
| 2014 |
Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, et al. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood. 124: 1312-9. PMID 25006122 DOI: 10.1182/Blood-2014-01-549212 |
0.357 |
|
| 2014 |
Mekinian A, Braun T, Decaux O, Falgarone G, Toussirot E, Raffray L, Omouri M, Gombert B, De Wazieres B, Buchdaul AL, Ziza JM, Launay D, Denis G, Madaule S, Rose C, et al. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine. 93: 1-10. PMID 24378738 DOI: 10.1097/Md.0000000000000011 |
0.319 |
|
| 2014 |
Coudé M, Braun T, Berrou J, Dupont M, Itzykson R, Masse A, Raffoux E, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C. Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 in a Panel of Human Acute Leukemia Cell Lines Blood. 124: 5957-5957. DOI: 10.1182/Blood.V124.21.5957.5957 |
0.382 |
|
| 2014 |
Braun T, Debache A, Roudot H, Lusina D, Thépot S, Eclache V, Martin A, Soret J, Harel S, Bréchignac S, Kelaidi C, Adès L, Fenaux P, Gardin C. Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report Blood. 124: 5610-5610. DOI: 10.1182/Blood.V124.21.5610.5610 |
0.35 |
|
| 2014 |
Vidal V, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Dombret H, Rohrlich P, Ades L, Chomienne C, Fenaux P, et al. BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 124: 3261-3261. DOI: 10.1182/Blood.V124.21.3261.3261 |
0.412 |
|
| 2014 |
Mekinian A, Grignano E, Braun T, Olivier D, Eric L, Nathalie C, jean Emmanuel K, Hamidou M, Puechal X, Park S, Toussirot E, Falgarone G, Launay D, Nathalie M, Trouiller S, et al. Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study Blood. 124: 3254-3254. DOI: 10.1182/Blood.V124.21.3254.3254 |
0.353 |
|
| 2014 |
Kelaidi C, Braun T, Lazarian G, Soret J, Cereja S, Eclache V, Lusina D, Adès L, Martin A, Fenaux P, Gardin C. Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA) Blood. 124: 1921-1921. DOI: 10.1182/Blood.V124.21.1921.1921 |
0.375 |
|
| 2013 |
Braun T, Fenaux P. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Practice & Research. Clinical Haematology. 26: 327-36. PMID 24507810 DOI: 10.1016/J.Beha.2013.09.003 |
0.351 |
|
| 2013 |
Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, Caillot D, Cornillon J, Dimicoli S, Etienne A, Galicier L, Garnier A, Girault S, Hunault-Berger M, Marolleau JP, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. British Journal of Haematology. 162: 489-97. PMID 23772757 DOI: 10.1111/Bjh.12415 |
0.366 |
|
| 2013 |
Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Lambert C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Annals of Hematology. 92: 621-31. PMID 23358617 DOI: 10.1007/S00277-013-1686-4 |
0.331 |
|
| 2013 |
Sebert M, Braun T, Gardin C, Martin A, Brechignac S, Harel S, Fenaux P, Ades L. Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study Blood. 122: 1539-1539. DOI: 10.1182/Blood.V122.21.1539.1539 |
0.39 |
|
| 2013 |
Braun T, Cherait A, Rigal M, Bréchignac S, Thépot S, Gardin C, Adès L, Fenaux P. P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70330-8 |
0.309 |
|
| 2013 |
Braun T, Raffoux E, Prebet T, Stamatoullas A, Bréchignac S, Dreyfus F, Samey B, Adès L, Vey N, Dombret H, Fenaux P, Gardin C. P-281 Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA) Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70328-X |
0.36 |
|
| 2013 |
Braun T, Miyara M, Itzykson R, Renneville A, Kosmider O, Gardin C, Solary E, Gorochov G, Fenaux P, Adès L. P-245 Effector CD4+CD45RA-CD25brightFoxp3bright regulatory T cells (eTregs) are significantly increased in chronic myelomonocytic leukemia (CMML) with TET2 mutations Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70292-3 |
0.346 |
|
| 2012 |
Natarajan-Amé S, Park S, Ades L, Vey N, Guerci-Bresler A, Cahn JY, Etienne G, Bordessoule D, Ravoet C, Legros L, Cheze S, Stamatoullas A, Berger E, Schmidt A, Charbonnier A, ... ... Braun T, et al. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. British Journal of Haematology. 158: 232-7. PMID 22571447 DOI: 10.1111/J.1365-2141.2012.09153.X |
0.415 |
|
| 2012 |
Prebet T, Braun T, Beyne-Rauzy O, Wattel E, Dreyfus F, Stamatoulas A, Ame S, Delaunay J, Raffoux E, Chermat F, Fenaux P, Vey N. Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure Blood. 120: 3825-3825. DOI: 10.1182/Blood.V120.21.3825.3825 |
0.308 |
|
| 2012 |
Vidal V, Sebert M, Thepot S, Braun T, Gardin C, Brechignac S, Fenaux P, Ades L. Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients Blood. 120: 3812-3812. DOI: 10.1182/Blood.V120.21.3812.3812 |
0.334 |
|
| 2012 |
Cluzeau T, Dhedin N, Huguet F, Raffoux E, Maury S, Mannone L, Escoffre-Barbe M, Le Calloch R, Delannoy A, Turlure P, Braun T, Vey N, Baruchel A, Dombret H, Boissel N. Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT) Blood. 120: 3561-3561. DOI: 10.1182/Blood.V120.21.3561.3561 |
0.31 |
|
| 2012 |
Braun T, Miyara M, Itzykson R, Renneville A, Kosmider O, Gardin C, Solary E, Gorochov G, Fenaux P, Ades L. Effector CD4+CD45RA−CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status. Blood. 120: 2808-2808. DOI: 10.1182/Blood.V120.21.2808.2808 |
0.364 |
|
| 2012 |
Sebert M, Vidal V, Eclache V, Thepot S, Braun T, Gardin C, Fenaux P, Ades L. Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA). Blood. 120: 2807-2807. DOI: 10.1182/Blood.V120.21.2807.2807 |
0.343 |
|
| 2012 |
Ades L, Renzis Bd, Jeddi R, Delaunay J, Braun T, Berger MH, Stamatoullas A, Sanhes L, Samey B, Chermat F, Meddeb B, Fenaux P. Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies Blood. 120: 1720-1720. DOI: 10.1182/Blood.V120.21.1720.1720 |
0.359 |
|
| 2011 |
Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, Royer B, Joly B, Vekhoff A, Lafon I, Sanhes L, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 118: 3824-31. PMID 21828134 DOI: 10.1182/Blood-2011-05-352039 |
0.344 |
|
| 2011 |
Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, et al. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leukemia Research. 35: 863-7. PMID 21396711 DOI: 10.1016/J.Leukres.2011.02.008 |
0.309 |
|
| 2011 |
Fain O, Braun T, Stirnemann J, Fenaux P. Manifestations systémiques et auto-immunes des syndromes myélodysplasiques Revue De MéDecine Interne. 32: 552-559. PMID 20850913 DOI: 10.1016/J.Revmed.2010.08.005 |
0.324 |
|
| 2011 |
Braun T, Raffoux E, Prebet T, Brechignac S, Stamatoullas A, Dreyfus F, Hebibi Z, Ades L, Vey N, Dombret H, Fenaux P, Gardin C. Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325) Blood. 118: 609-609. DOI: 10.1182/Blood.V118.21.609.609 |
0.329 |
|
| 2011 |
Sibon D, Berceanu A, Ghez D, Foissac F, Kammoun L, Braun T, Caillot D, Ojeda-Uribe M, Guieze R, Berthon C, Sanhes L, Gruson B, Bouscary D, Recher C, Stalnikiewicz L, et al. Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience Blood. 118: 2623-2623. DOI: 10.1182/Blood.V118.21.2623.2623 |
0.339 |
|
| 2011 |
Recher C, Thomas X, Tavernier E, Lioure B, Pautas C, Perrot A, Braun T, Cluzeau T, Malfuson J, Tamburini J, Berthon C, Magda A, Himberlin C, Botton Sd, Randriamalala E, et al. Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse Blood. 118: 2603-2603. DOI: 10.1182/Blood.V118.21.2603.2603 |
0.369 |
|
| 2010 |
Prebet T, Braun T, Rauzy OB, Dreyfus F, Stamatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Salanoubat C, Mathieu I, Chermat F, Ades L, Fenaux P, Vey N. A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study Blood. 116: 4003-4003. DOI: 10.1182/Blood.V116.21.4003.4003 |
0.306 |
|
| 2010 |
Droin N, Itzykson R, Rameau P, Morabito M, Braun T, Louache F, Zhang Y, Botton SD, Cordonnier C, Quesnel B, Fenaux P, Vainchenker W, Solary E. Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML Blood. 116: 3997-3997. DOI: 10.1182/Blood.V116.21.3997.3997 |
0.337 |
|
| 2009 |
Kelaidi C, Beyne-Rauzy O, Braun T, Cougoul P, Ades L, Pillard F, Lamberto C, Jernival T, Mortera E, Guerci A, Choufi B, Stamatoullas A, Slama B, Renzis BD, Ame S, et al. High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study. Blood. 114: 3812-3812. DOI: 10.1182/Blood.V114.22.3812.3812 |
0.322 |
|
| 2008 |
Grosjean-Raillard J, Tailler M, Adès L, Perfettini JL, Fabre C, Braun T, De Botton S, Fenaux P, Kroemer G. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 28: 1099-109. PMID 19079347 DOI: 10.1038/Onc.2008.457 |
0.784 |
|
| 2008 |
Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 13: 1148-61. PMID 18670883 DOI: 10.1007/s10495-008-0243-4 |
0.801 |
|
| 2008 |
Braun T, Fenaux P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology. 141: 576-86. PMID 18410457 DOI: 10.1111/J.1365-2141.2008.07099.X |
0.395 |
|
| 2008 |
Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood. 111: 2170-80. PMID 17925489 DOI: 10.1182/Blood-2007-07-100362 |
0.792 |
|
| 2007 |
Braun T, Carvalho G, Grosjean J, Ades L, Fabre C, Boehrer S, Debili N, Fenaux P, Kroemer G. Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation. Apoptosis : An International Journal On Programmed Cell Death. 12: 1101-8. PMID 17245643 DOI: 10.1007/S10495-006-0030-Z |
0.717 |
|
| 2007 |
Fabre C, Carvalho G, Tasdemir E, Braun T, Adès L, Grosjean J, Boehrer S, Métivier D, Souquère S, Pierron G, Fenaux P, Kroemer G. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 26: 4071-83. PMID 17213804 DOI: 10.1038/Sj.Onc.1210187 |
0.786 |
|
| 2007 |
Carvalho G, Fabre C, Braun T, Grosjean J, Ades L, Agou F, Tasdemir E, Boehrer S, Israel A, Véron M, Fenaux P, Kroemer G. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 26: 2299-307. PMID 17043643 DOI: 10.1038/Sj.Onc.1210043 |
0.785 |
|
| 2007 |
Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G. The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML. Blood. 110: 399-399. DOI: 10.1182/Blood.V110.11.399.399 |
0.792 |
|
| 2007 |
Boehrer S, Ades L, Galluzzi L, Olaussen K, Braun T, Grosjean J, Fabre C, de Botton S, Fenaux P, Kroemer G. Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways. Blood. 110: 2438-2438. DOI: 10.1182/Blood.V110.11.2438.2438 |
0.789 |
|
| 2007 |
Boehrer S, Adès L, Braun T, Grosjean J, Fabre C, Fenaux P, Kroemer G. P057 Abrogation of the DNA-damage response in AML versus MDS cell lines Leukemia Research. 31: S71. DOI: 10.1016/S0145-2126(07)70127-3 |
0.706 |
|
| 2007 |
Boehrer S, Adàs L, Braun T, Galluzzi L, Grosjean J, Fabre C, de Botton S, Gardin C, Fenaux P, Kroemer G. P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML Leukemia Research. 31: S62. DOI: 10.1016/S0145-2126(07)70109-1 |
0.735 |
|
| 2006 |
Coquelle A, Mouhamad S, Pequignot MO, Braun T, Carvalho G, Vivet S, Métivier D, Castedo M, Kroemer G. Enrichment of non-synchronized cells in the G1, S and G2 phases of the cell cycle for the study of apoptosis. Biochemical Pharmacology. 72: 1396-404. PMID 16765323 DOI: 10.1016/J.Bcp.2006.04.014 |
0.473 |
|
| 2006 |
Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death and Differentiation. 13: 748-58. PMID 16498458 DOI: 10.1038/Sj.Cdd.4401874 |
0.727 |
|
| 2006 |
Coquelle A, Mouhamad S, Pequignot MO, Braun T, Carvalho G, Vivet S, Métivier D, Castedo M, Kroemer G. Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Cell Death and Differentiation. 13: 873-5. PMID 16498456 DOI: 10.1038/Sj.Cdd.4401881 |
0.437 |
|
| 2006 |
Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, Kiladjian JJ, Ribrag V, Fenaux P, Kroemer G. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 107: 1156-65. PMID 16223780 DOI: 10.1182/Blood-2005-05-1989 |
0.602 |
|
| 2005 |
Gonzalez-Polo RA, Carvalho G, Braun T, Decaudin D, Fabre C, Larochette N, Perfettini JL, Djavaheri-Mergny M, Youlyouz-Marfak I, Codogno P, Raphael M, Feuillard J, Kroemer G. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene. 24: 7503-13. PMID 16091749 DOI: 10.1038/Sj.Onc.1208907 |
0.771 |
|
| 2005 |
Braun T, Carvalho G, Vozenin M, Kiladjian J, Hirsch F, Fenaux P, Kroemer G. P-45 NF-κB is a potential therapeutictarget in high risk MDS: Induction of apoptosis by bortezomib and BAY 11-7082 Leukemia Research. 29: S41. DOI: 10.1016/S0145-2126(05)80109-2 |
0.5 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Itzykson R, Kosmider O, Renneville A, Morabito M, Berthon C, Ades L, Fenaux P, Beyne-Rauzy O, Braun T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, et al. Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML) Blood. 120: 3811-3811. DOI: 10.1182/Blood.V120.21.3811.3811 |
0.299 |
|
| 2010 |
Cereja S, Brechignac S, Ades L, Braun T, Boehrer S, Hebibi Z, Sapena R, Beyne-Rauzy O, Vey N, Dombret H, Bordessoule D, Dreyfus F, Fenaux P, Gardin C. Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS Blood. 116: 1868-1868. DOI: 10.1182/Blood.V116.21.1868.1868 |
0.297 |
|
| 2016 |
Arana R, Lusina D, Braun T, Letestu R, Gardin C, Martin A. HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens. Journal of Clinical Pathology. PMID 27484914 DOI: 10.1136/Jclinpath-2016-203850 |
0.297 |
|
| 2010 |
Braun T, Droin N, Renzis Bd, Dreyfus F, Laribi K, Bouabdallah K, Charbonnier A, Cordonnier C, Lafon I, Récher C, Vey N, Bastie JM, Besancon A, Beyne-Rauzy O, Joly B, et al. A Phase II Study of Decitabine In Advanced Chronic Myelomonocytic Leukemia (CMML) Blood. 116: 1873-1873. DOI: 10.1182/Blood.V116.21.1873.1873 |
0.296 |
|
| 2016 |
Rammaert B, Candon S, Maunoury C, Bougnoux ME, Jouvion G, Braun T, Correas JM, Lortholary O. Thalidomide for steroid-dependent chronic disseminated candidiasis after stem cell transplantation: A case report. Transplant Infectious Disease : An Official Journal of the Transplantation Society. PMID 27862711 DOI: 10.1111/Tid.12637 |
0.295 |
|
| 2016 |
Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related? British Journal of Haematology. PMID 27662562 DOI: 10.1111/Bjh.14323 |
0.292 |
|
| 2008 |
Braun T, de Botton S, Taksin A, Park S, Beyne-Rauzy O, Chevret S, Fontenay M, Cassinat B, Lazareth A, Eclache V, Terre C, Vey N, Guerci A, Dreyfus F, Bordessoule D, et al. Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases. Blood. 112: 1657-1657. DOI: 10.1182/Blood.V112.11.1657.1657 |
0.291 |
|
| 2009 |
Braun T, Botton Sd, Guenda K, Leroux G, Taksin A, Park S, Beyne-Rauzy O, Chevret S, Lazareth A, Terre C, Eclache V, Fenaux P, Ades L. P033 Isolated del 20q defines a subgroup of MDS patients with lower blast counts and more frequent thrombocytopenia Leukemia Research. 33. DOI: 10.1016/S0145-2126(09)70113-4 |
0.291 |
|
| 2019 |
Fraison JB, Grignano E, Braun T, Adès L, Chollet-Martin S, Roland-Nicaise P, Fenaux P, Fain O, Mekinian A. Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia & Lymphoma. 1-3. PMID 30958078 DOI: 10.1080/10428194.2019.1599114 |
0.289 |
|
| 2011 |
Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoulas A, Wattel E, Ame S, Raffoux E, Ades L, Fenaux P, Vey N. 191 Vorinostat and low dose cytarabine for high risk myelodysplastic syndromes with azacytidine failure: the GFM-VOR2007 study Leukemia Research. 35. DOI: 10.1016/S0145-2126(11)70193-X |
0.287 |
|
| 2015 |
Fraison J, Mekinian A, Grignano E, Kahn J, Arlet J, Decaux O, Guillaume D, Buchdahl A, Omouri M, Maigne G, Aouba A, Leon N, Berthier S, Liozon E, Park S, ... ... Braun T, et al. Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Blood. 126: 1695-1695. DOI: 10.1182/Blood.V126.23.1695.1695 |
0.283 |
|
| 2013 |
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2428-36. PMID 23690417 DOI: 10.1200/Jco.2012.47.3314 |
0.28 |
|
| 2014 |
Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Charbonnier A, Adès L, Fenaux P, Vey N. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leukemia Research. 38: 29-33. PMID 23953882 DOI: 10.1016/J.Leukres.2013.07.023 |
0.28 |
|
| 2019 |
Guillaume-Jugnot P, Badoglio M, Labopin M, Terriou L, Yakoub-Agha I, Martin T, Lioure B, Marjanovic Z, Blaise D, Nguyen S, Pugnet G, Huynh A, Deligny C, Seinturier C, Garban F, ... ... Braun T, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clinical Rheumatology. PMID 30663016 DOI: 10.1007/S10067-019-04435-2 |
0.28 |
|
| 2016 |
Grignano E, Mekinian A, Braun T, Liozon E, Hamidou M, Decaux O, Puéchal X, Kahn JE, Schoindre Y, Rossignol J, Lortholary O, Lioger B, Hermine O, Park S, Ades L, et al. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leukemia Research. 47: 136-141. PMID 27337291 DOI: 10.1016/J.Leukres.2016.05.013 |
0.277 |
|
| 2015 |
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford, England). PMID 26350487 DOI: 10.1093/Rheumatology/Kev294 |
0.277 |
|
| 2019 |
Duchmann M, Micol J, Duployez N, Raffoux E, Thomas X, Marolleau J, Braun T, Ades L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, et al. Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML Blood. 134: 1416-1416. DOI: 10.1182/Blood-2019-127082 |
0.276 |
|
| 2016 |
Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications. 7: 10767. PMID 26908133 DOI: 10.1038/Ncomms10767 |
0.273 |
|
| 2017 |
Selimoglu-Buet D, Badaoui B, Benayoun E, Toma A, Fenaux P, Quesnel B, Etienne G, Braun T, Abermil N, Morabito M, Droin N, Solary E, Wagner-Ballon O. Accumulation of classical monocytes defines a subgroup of MDS that frequently evolve into CMML. Blood. PMID 28611023 DOI: 10.1182/Blood-2017-04-779579 |
0.272 |
|
| 2015 |
Sebert M, Ades L, Stamatoullas A, Braun T, Delaunay J, Renzis Bd, Jeddi R, Meddeb B, Berger MH, Samey B, Chermat F, Chaffaut C, Chevert S, Fenaux P. 123 Azacitidine (Aza) Combined With Idarubicin (Ida) In Higher Risk Mds (Hrmds) – Results Of A Phase I/Ii Study By The Gfm Leukemia Research. 39. DOI: 10.1016/S0145-2126(15)30124-7 |
0.266 |
|
| 2013 |
Sebert M, Vidal V, Eclache V, Thepot S, Itzykson R, Braun T, Gardin C, Fenaux P, Ades L. P-284 Impact of cytogenetics and cytogeneticresponse on outcome in MDS treated with azacitidine (AZA) Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70331-X |
0.265 |
|
| 2011 |
Cereja S, Brechignac S, Adès L, Braun T, Boehrer S, Hebibi Z, Sapena R, Beyne-Rauzy O, Vey N, Dombret H, Bordessoule D, Dreyfus F, Fenaux P, Gardin C. 210 Should immunosuppressive therapy (1ST) be used more often in lower risk MDS Leukemia Research. 35. DOI: 10.1016/S0145-2126(11)70212-0 |
0.263 |
|
| 2021 |
Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 138: 507-519. PMID 34410352 DOI: 10.1182/blood.2021011103 |
0.261 |
|
| 2017 |
Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, et al. A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents Leukemia Research. 55. DOI: 10.1016/S0145-2126(17)30157-1 |
0.258 |
|
| 2015 |
Fraison JB, Mekinian A, Braun T, Grignano E, Ades L, Brechignac S, Gardin C, Bourgarit-Durand A, Andres E, Fenaux P, Fain O. Hypervitaminémie B12 dans les syndromes myélodysplasiques : facteur de mauvais pronostic ? Revue De MéDecine Interne. 36. DOI: 10.1016/J.Revmed.2015.10.297 |
0.253 |
|
| 2015 |
Fraison JB, Mekinian A, Braun T, Grignano E, Ades L, Brechignac S, Gardin C, Bourgarit A, Chollet-Martin S, Nicaise PR, Fenaux P, Fain O. Fréquence des auto-anticorps dans les syndromes myélodysplasiques avec et sans manifestations auto-immunes cliniques Revue De MéDecine Interne. 36. DOI: 10.1016/J.Revmed.2015.03.309 |
0.253 |
|
| 2022 |
de Botton S, Cluzeau T, Vigil CE, Cook R, Rousselot P, Rizzieri DA, Liesveld JL, Fenaux P, Braun T, Banos A, Jurcic JG, Sekeres MA, Savona MR, Roboz GJ, Bixby D, et al. Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML. Blood Advances. PMID 36477975 DOI: 10.1182/bloodadvances.2022008806 |
0.25 |
|
| 2021 |
Itzykson RA, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, et al. Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy. Blood. PMID 34046677 DOI: 10.1182/blood.2021011103 |
0.249 |
|
| 2013 |
Ades L, Renzis BD, Jeddi R, Delaunay J, Braun T, Hunault-Berger M, Stamatoullas A, Sanhes L, Samey B, Chermat F, Meddeb B, Fenaux P. O-011 Azacitidine (AZA) + idarubicin (IDA) in untreated high-risk MDS – A GFM phase I/II study Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70033-X |
0.247 |
|
| 2013 |
Mirouse A, Virone A, Gobert D, Soussan M, Braun T, Gardin C, Fenaux P, Mekinian A, Fain O. Abcès musculaires aseptiques associés à un syndrome myélodysplasique Revue De MéDecine Interne. 34. DOI: 10.1016/J.Revmed.2013.03.142 |
0.244 |
|
| 2011 |
Braun T, Droin N, Itzykson R, Renzis Bd, Dreyfus F, Laribi K, Boabdallah K, Charbonnier A, Cordonnier C, Lafon I, Recher C, Vey N, Bastie J-, Besançon A, Beyne-Rauzy O, et al. 162 A phase II study of decitabine in advanced chronic myelomonocytic leukemia (CMML) Leukemia Research. 35. DOI: 10.1016/S0145-2126(11)70164-3 |
0.243 |
|
| 2022 |
Adès L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Dimicoli-Salazar S, Braun T, et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. British Journal of Haematology. PMID 35438802 DOI: 10.1111/bjh.18193 |
0.243 |
|
| 2023 |
Stein EM, de Botton S, Cluzeau T, Pigneux A, Liesveld JL, Cook RJ, Rousselot P, Rizzieri DA, Braun T, Roboz GJ, Lebon D, Heiblig M, Baker K, Volkert A, Paul S, et al. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with gene overexpression. Leukemia & Lymphoma. 1-10. PMID 37571998 DOI: 10.1080/10428194.2023.2243356 |
0.239 |
|
| 2009 |
Chehensse C, Braun T, Morin A-, Stirnemann J, Agranat P, Boukari L, Aras N, Kiladjian J-, Ziol M, Fenaux P, Fain O. Fièvre prolongée au cours d’un syndrome 5q– révélant une transformation blastique extramédullaire Revue De MéDecine Interne. 30: 886-889. PMID 19748163 DOI: 10.1016/J.Revmed.2009.07.010 |
0.238 |
|
| 2012 |
Mekinian A, Decaux O, Braun T, Fenaux P, Fain O, Falgarone G, Toussirot E, Raffray L, Gombert B, Wazieres B, Buchdaul AL, Ziza J-, Launay D, Denis G, Madaule S, et al. Caractéristiques des manifestations articulaires inflammatoires au cours des syndromes myélodysplasiques Revue De MéDecine Interne. 33. DOI: 10.1016/J.Revmed.2012.10.047 |
0.238 |
|
| 2014 |
Grignano E, Mekinian A, Braun T, Liozon E, Hamidou M, Decaux O, Puéchal X, Kahn JE, Schoindre Y, Rossignol J, Fenaux P, Fain O. Manifestations auto-immunes et maladies inflammatoires associées aux leucémies myélomonocytaires chroniques : étude rétrospective française Revue De MéDecine Interne. 35. DOI: 10.1016/J.Revmed.2014.10.040 |
0.233 |
|
| 2014 |
Fraison JB, Mekinian A, Braun T, Kahn JE, Park S, Silva NM, Berthier S, Liozon E, Grosbois B, Lortholary O, Fenaux P, Fain O, Denis G, Buchdahl AL, Omouri M, et al. Efficacité de l’azacytidine dans les manifestations auto immunes associées aux syndromes myélodysplasiques : 23 observations Revue De MéDecine Interne. 35. DOI: 10.1016/J.Revmed.2014.10.041 |
0.233 |
|
| 2017 |
Drevon L, Renneville A, Marceau A, Raynaud S, Maarek O, Dimicoli-Salazar S, Cuccuini W, Bidet A, Eclache V, Lusina D, Park S, Stamatoullas A, Delhommeau F, Berthon C, Berkaoui I, ... ... Braun T, et al. MDS with Isolated Trisomy 8: A type of MDS Frequently Associated with Myeloproliferative Features? A Report by the GFM Leukemia Research. 55. DOI: 10.1016/S0145-2126(17)30146-7 |
0.232 |
|
| 2022 |
Dal Bello R, Pasanisi J, Joudinaud R, Duchmann M, Pardieu B, Ayaka P, Di Feo G, Sodaro G, Chauvel C, Kim R, Vasseur L, Chat L, Ling F, Pacchiardi K, Vaganay C, ... ... Braun T, et al. A multiparametric niche-like drug screening platform in acute myeloid leukemia. Blood Cancer Journal. 12: 95. PMID 35750691 DOI: 10.1038/s41408-022-00689-3 |
0.231 |
|
| 2021 |
Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie SP, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood. PMID 33881523 DOI: 10.1182/blood.2020010165 |
0.229 |
|
| 2023 |
de Botton S, Fenaux P, Yee KWL, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove CS, Jonas BA, Khwaja A, Legrand O, Peterlin P, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances. PMID 36724515 DOI: 10.1182/bloodadvances.2022009411 |
0.226 |
|
| 2024 |
Groh M, Fenwarth L, Labro M, Boudry A, Fournier E, Wemeau M, Marceau-Renaut A, Daltro de Oliveira R, Abraham J, Barry M, Blanche P, Bodard Q, Braun T, Chebrek S, Decamp M, et al. Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study. American Journal of Hematology. PMID 38563187 DOI: 10.1002/ajh.27306 |
0.224 |
|
| 2020 |
Playe M, Siavellis J, Braun T, Soussan M. FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings. Clinical Nuclear Medicine. PMID 32453077 DOI: 10.1097/Rlu.0000000000003113 |
0.224 |
|
| 2015 |
Fraison JB, Mekinian A, Grignano E, Kahn JE, Arlet JB, Silva NM, Berthier S, Liozon E, Denis G, Buchdahl AL, Omouri M, Grosbois B, Park S, Bourgarit-Durand A, Rossignol J, ... ... Braun T, et al. 280 Efficacy Of Azacitidine (Aza) In Autoimmune Disorders (Aid) Associated With Mds Leukemia Research. 39. DOI: 10.1016/S0145-2126(15)30281-2 |
0.22 |
|
| 2013 |
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Fenaux P, Fain O. Manifestations auto-immunes au cours de syndromes myélodysplasiques Revue De MéDecine Interne. 34. DOI: 10.1016/J.Revmed.2013.10.062 |
0.219 |
|
| 2021 |
Michallet M, Sobh M, Morisset S, Deloire A, Raffoux E, de Botton S, Caillot D, Chantepie S, Girault S, Berthon C, Bertoli S, Lepretre S, Leguay T, Castaigne S, Marolleau JP, ... ... Braun T, et al. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group. Clinical Lymphoma, Myeloma & Leukemia. PMID 34895843 DOI: 10.1016/j.clml.2021.10.011 |
0.213 |
|
| 2009 |
Bibi-Triki T, Aras N, Braun T, Lautridou C, Boukari L, Morin AS, Maquarre E, Stirnemann J, Brichler S, Laurian Y, Fain O. Plasmocytose sanguine et médullaire au cours de la dengue : une observation Revue De MéDecine Interne. 30: 274-276. PMID 18584920 DOI: 10.1016/J.Revmed.2008.05.012 |
0.206 |
|
| 2021 |
Kayser S, Schlenk RF, Lebon D, Carre M, Götze KS, Stölzel F, Berceanu A, Schäfer-Eckart K, Peterlin P, Hicheri Y, Rahme R, Raffoux E, Chermat F, Krause SW, Aulitzky WE, ... ... Braun T, et al. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. Haematologica. PMID 34047178 DOI: 10.3324/haematol.2021.278722 |
0.205 |
|
| 2012 |
Hiepe F, Alexander T, Peukert R, Rubbert A, Rech J, Braun T, Schott G, Wiesener M, Eckardt KU, Baeuerle M, Reisch A, Hoyer B, Taddeo A, Burmester G, Schett G, et al. Refractory SLE patients respond to the proteasome inhibitor bortezomib Annals of the Rheumatic Diseases. 71: A15.3-A16. DOI: 10.1136/ANNRHEUMDIS-2011-201230.34 |
0.204 |
|
| 2015 |
Fraison JB, Mekinian A, Braun T, Grignano E, Adès L, Brechignac S, Gardin C, Bourgarit-Durand A, Chollet-Martin S, Nicaise-Roland P, Fenaux P, Fain O. 279 Frequency Of Autoantibodies (Aab) In Mds With And Without Clinical Autoimmune Disorders (Aid) Leukemia Research. 39. DOI: 10.1016/S0145-2126(15)30280-0 |
0.2 |
|
| 2013 |
Ghrenassia E, Mekinian A, Paclet M-, Nahon P, Braun T, Morin A-, Fain O. Une élévation importante et isolée des ASAT : pensez aux macro-ASAT ! Revue De MéDecine Interne. 34. DOI: 10.1016/J.Revmed.2013.03.173 |
0.197 |
|
| 2003 |
Boukari L, Stirnemann J, Braun T, Fain O, Kettaneh A, Letellier E, Prévot S, Thomas M. Fistule aorto-œsophagienne sur corps étranger: un diagnostic souvent difficile et une évolution souvent fatale Revue De MéDecine Interne. 24: 4-6. DOI: 10.1016/S0248-8663(03)80558-1 |
0.197 |
|
| 2006 |
Stirnemann J, Prévot S, Letellier E, Rouaghe S, Boukari L, Braun T, Kettaneh A, Fain O. Une arête de poisson mortelle Revue De MéDecine Interne. 27: 561-562. PMID 16310289 DOI: 10.1016/J.Revmed.2005.10.002 |
0.196 |
|
| 2015 |
Braun T, Meng W, Shang H, Li S, Sloboda DM, Ehrlich L, Lange K, Xu H, Henrich W, Dudenhausen JW, Plagemann A, Newnham JP, Challis JR. Early dexamethasone treatment induces placental apoptosis in sheep. Reproductive Sciences (Thousand Oaks, Calif.). 22: 47-59. PMID 25063551 DOI: 10.1177/1933719114542028 |
0.192 |
|
| 2020 |
Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, Merabet F, Mekinian A, Braun T, Damaj G, Delmer A, Cymbalista F. Autoimmune haemolytic anaemia associated with COVID-19 infection. British Journal of Haematology. PMID 32374906 DOI: 10.1111/Bjh.16794 |
0.189 |
|
| 2023 |
Rahmé R, Braun T, Manfredi JJ, Fenaux P. TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Biomedicines. 11. PMID 37189770 DOI: 10.3390/biomedicines11041152 |
0.182 |
|
| 2008 |
Boukari L, Caux F, Levy A, Braun T, Aras N, Stirnemann J, Morin A-, Agranat P, Ziol M, Fain O. Lymphome angiotrope à grandes cellules B pseudosclérodermique Revue De MéDecine Interne. 29. DOI: 10.1016/J.Revmed.2008.10.148 |
0.177 |
|
| 2019 |
Dal Bello R, Adès L, Braun T, Pasanisi J, Fournier E, Bérthon C, Clappier E, Raffoux E, Lebon D, Cluzeau T, Roumier C, Plesa A, Celli Lebras K, Dombret H, Preudhomme C, et al. PF211 MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL Hemasphere. 3: 57. DOI: 10.1097/01.HS9.0000559060.69683.DA |
0.177 |
|
| 2013 |
Voll R, Alexander T, Peukert R, Rubbert A, Rech J, Braun T, Wiesener M, Eckardt K, Hoyer B, Taddeo A, Reisch A, Burmester G, Radbruch A, Schett G, Hiepe F. SAT0203 Successful treatment of refractory SLE patients with the proteasome inhibitor bortezomib – a case series Annals of the Rheumatic Diseases. 71: 540.3-540. DOI: 10.1136/ANNRHEUMDIS-2012-EULAR.3150 |
0.169 |
|
| 2022 |
Dal Bello R, Pacchiardi K, Chauvel C, Adès L, Braun T, Pasanisi J, Fournier E, Berthon C, Clappier E, Raffoux E, Lebon D, Cluzeau T, Roumier C, Plesa A, Celli-Lebras K, et al. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively. Hemasphere. 7: e819. PMID 36570694 DOI: 10.1097/HS9.0000000000000819 |
0.164 |
|
| 2021 |
Segler A, Braun T, Fischer HS, Dukatz R, Weiss CR, Schwickert A, Jäger C, Bührer C, Henrich W. Feasibility of Umbilical Cord Blood Collection in Neonates at Risk of Brain Damage-A Step Toward Autologous Cell Therapy for a High-risk Population. Cell Transplantation. 30: 963689721992065. PMID 33631961 DOI: 10.1177/0963689721992065 |
0.162 |
|
| 2021 |
Shamloul A, Steinemann G, Roos K, Liem CH, Bernd J, Braun T, Zakrzewicz A, Berkholz J. The Methyltransferase Smyd1 Mediates LPS-Triggered Up-Regulation of IL-6 in Endothelial Cells. Cells. 10. PMID 34944023 DOI: 10.3390/cells10123515 |
0.153 |
|
| 2023 |
Vignal N, Kelly L, Lengline E, Cabannes-Hamy A, Siavellis J, Ghez D, Sauvageon H, Braun T, Jacqz-Aigrain E, Kohn M, Rousselot P, Puissant A, Raffoux E, Mourah S, Goldwirt L. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia patients. Haematologica. PMID 36794507 DOI: 10.3324/haematol.2022.282596 |
0.148 |
|
| 2009 |
Fain O, Gérin M, Bibi-Triki T, Braun T, Fenaux P. [Relapsing polychondritis and chronic myelomonocytic leukemia]. La Revue Du Praticien. 59: 1350. PMID 20058752 |
0.136 |
|
| 2004 |
Averbeck M, Braun T, Pfeifer G, Sleeman J, Dudda J, Martin SF, Kremer B, Aktories K, Simon JC, Termeer C. Early cytoskeletal rearrangement during dendritic cell maturation enhances synapse formation and Ca(2+) signaling in CD8(+) T cells. European Journal of Immunology. 34: 2708-19. PMID 15368287 DOI: 10.1002/eji.200425355 |
0.134 |
|
| 2022 |
Dieckmann L, Cruceanu C, Lahti-Pulkkinen M, Lahti J, Kvist T, Laivuori H, Sammallahti S, Villa PM, Suomalainen-König S, Rancourt RC, Plagemann A, Henrich W, Eriksson JG, Kajantie E, Entringer S, ... Braun T, et al. Reliability of a novel approach for reference-based cell type estimation in human placental DNA methylation studies. Cellular and Molecular Life Sciences : Cmls. 79: 115. PMID 35113241 DOI: 10.1007/s00018-021-04091-3 |
0.127 |
|
| 2018 |
Shang H, Sun L, Braun T, Si Q, Tong J. Revealing the action mechanisms of dexamethasone on the birth weight of infant using RNA-sequencing data of trophoblast cells. Medicine. 97: e9653. PMID 29369181 DOI: 10.1097/MD.0000000000009653 |
0.124 |
|
| 2014 |
Nutman A, Glick R, Temkin E, Hoshen M, Edgar R, Braun T, Carmeli Y. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20: O1028-34. PMID 24930471 DOI: 10.1111/1469-0691.12716 |
0.121 |
|
| 2008 |
Fain O, Braun T, Winterman S, Agranat P. [Plasmocytoma]. La Revue Du Praticien. 58: 2097. PMID 19213535 |
0.12 |
|
| 2024 |
Abbas H, Derkaoui DK, Jeammet L, Adicéam E, Tiollier J, Sicard H, Braun T, Poyet JL. Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate. Biomolecules. 14. PMID 38275765 DOI: 10.3390/biom14010136 |
0.12 |
|
| 2024 |
Rahmé R, Braun T. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia? Journal of Clinical Medicine. 13. PMID 38256681 DOI: 10.3390/jcm13020549 |
0.12 |
|
| 2023 |
Henrich W, Dückelmann A, Braun T, Hinkson L. Uterine packing with chitosan-covered tamponade to treat postpartum hemorrhage. American Journal of Obstetrics and Gynecology. 230: S1061-S1065. PMID 38462249 DOI: 10.1016/j.ajog.2022.11.1297 |
0.12 |
|
| 2021 |
Zakine E, Schell B, Battistella M, Vignon-Pennamen MD, Chasset F, Mahévas T, Cordoliani F, Adès L, Sébert M, Delaleu J, Jachiet M, Lepelletier C, Lemaire P, Chauvel C, Dhouaieb B, ... ... Braun T, et al. UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome. Jama Dermatology. PMID 34495287 DOI: 10.1001/jamadermatol.2021.3344 |
0.117 |
|
| 2018 |
Becker M, Maring JA, Schneider M, Herrera Martin AX, Seifert M, Klein O, Braun T, Falk V, Stamm C. Towards a Novel Patch Material for Cardiac Applications: Tissue-Specific Extracellular Matrix Introduces Essential Key Features to Decellularized Amniotic Membrane. International Journal of Molecular Sciences. 19. PMID 29596384 DOI: 10.3390/ijms19041032 |
0.11 |
|
| 2021 |
Kennedy KM, Bellissimo CJ, Breznik JA, Barrett J, Braun T, Bushman FD, De Goffau M, Elovitz MA, Heimesaat MM, Konnikova L, Koren O, Parry S, Rossi L, Segata N, Simmons RA, et al. Over-celling fetal microbial exposure. Cell. 184: 5839-5841. PMID 34822779 DOI: 10.1016/j.cell.2021.10.026 |
0.11 |
|
| 2022 |
Grambow-Velilla J, Braun T, Pop G, Louzoun A, Soussan M. Aortitis PET Imaging in VEXAS Syndrome: A Case Report. Clinical Nuclear Medicine. 48: e67-e68. PMID 36607374 DOI: 10.1097/RLU.0000000000004506 |
0.109 |
|
| 2022 |
Braun T. An unexpected partnership targeting FLT3wt AML. Blood. 140: 2529-2530. PMID 36520473 DOI: 10.1182/blood.2022017344 |
0.102 |
|
| 2010 |
Braun T, Brauer M, Fuchs I, Czernik C, Dudenhausen JW, Henrich W, Sarioglu N. Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome. Fetal Diagnosis and Therapy. 27: 191-203. PMID 20357423 DOI: 10.1159/000305096 |
0.098 |
|
| 2013 |
Virone A, Mekinian A, Braun T, Agranat P, Fain O. [Pyothorax-associated lymphoma]. La Revue Du Praticien. 63: 765. PMID 23923749 |
0.098 |
|
| 2023 |
Paping A, Ehrlich L, Melchior K, Ziska T, Wippermann W, Starke A, Heinichen K, Henrich W, Braun T. A Sustainable Translational Sheep Model for Planned Cesarean Delivery of Contraction-Free Ewes. Reproductive Sciences (Thousand Oaks, Calif.). PMID 37848643 DOI: 10.1007/s43032-023-01365-y |
0.095 |
|
| 2015 |
Xu H, Bionaz M, Sloboda DM, Ehrlich L, Li S, Newnham JP, Dudenhausen JW, Henrich W, Plagemann A, Challis JR, Braun T. The dilution effect and the importance of selecting the right internal control genes for RT-qPCR: a paradigmatic approach in fetal sheep. Bmc Research Notes. 8: 58. PMID 25881111 DOI: 10.1186/s13104-015-0973-7 |
0.093 |
|
| 2023 |
Paping A, Basler C, Ehrlich L, Fasting C, Melchior K, Ziska T, Thiele M, Duda GN, Timm S, Ochs M, Rancourt RC, Henrich W, Braun T. Uterine scars after caesarean delivery: From histology to the molecular and ultrastructural level. Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society. PMID 37955528 DOI: 10.1111/wrr.13127 |
0.093 |
|
| 2023 |
Daskalakis G, Pergialiotis V, Domellöf M, Ehrhardt H, Di Renzo GC, Koç E, Malamitsi-Puchner A, Kacerovsky M, Modi N, Shennan A, Ayres-de-Campos D, Gliozheni E, Rull K, Braun T, Beke A, et al. European guidelines on perinatal care: corticosteroids for women at risk of preterm birth. The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 36: 2160628. PMID 36689999 DOI: 10.1080/14767058.2022.2160628 |
0.088 |
|
| 2021 |
Schwickert A, Henrich W, Vogel M, Melchior K, Ehrlich L, Ochs M, Braun T. Placenta Percreta Presents with Neoangiogenesis of Arteries with Von Willebrand Factor-Negative Endothelium. Reproductive Sciences (Thousand Oaks, Calif.). PMID 34766259 DOI: 10.1007/s43032-021-00763-4 |
0.087 |
|
| 2021 |
Chantraine F, Stefanovic V, Braun T, Calda P, Martinelli P, Collins SL. When a rare condition creates a scientific society: The history of the International Society for Placenta Accreta Spectrum (IS-PAS). Acta Obstetricia Et Gynecologica Scandinavica. 100: 3-6. PMID 33811334 DOI: 10.1111/aogs.14077 |
0.084 |
|
| 2021 |
Schwickert A, van Beekhuizen HJ, Bertholdt C, Fox KA, Kayem G, Morel O, Rijken MJ, Stefanovic V, Strindfors G, Weichert A, Weizsaecker K, Braun T. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): a multinational database study. Acta Obstetricia Et Gynecologica Scandinavica. PMID 33524163 DOI: 10.1111/aogs.14103 |
0.08 |
|
| 2021 |
Biele C, Kaufner L, Nonnenmacher A, von Weizsäcker K, Muallem MZ, Henrich W, Braun T. Reply to: "Hysterectomy versus continuing conservative management: which is better for disseminated intravascular coagulation?"; Shinya Matsuzaki, MD, PhD, Yoshikazu Nagase, MD, Masayuki Endo, MD, PhD, Tadashi Kimura, MD, PhD. Archives of Gynecology and Obstetrics. PMID 33544204 DOI: 10.1007/s00404-021-05964-5 |
0.079 |
|
| 2020 |
Braun T, Filleböck V, Metze B, Bührer C, Plagemann A, Henrich W. Long term alterations of growth after antenatal steroids in preterm twin pregnancies. Journal of Perinatal Medicine. PMID 33010142 DOI: 10.1515/jpm-2020-0204 |
0.076 |
|
| 2009 |
Braun T, Li S, Sloboda DM, Li W, Audette MC, Moss TJ, Matthews SG, Polglase G, Nitsos I, Newnham JP, Challis JR. Effects of maternal dexamethasone treatment in early pregnancy on pituitary-adrenal axis in fetal sheep. Endocrinology. 150: 5466-77. PMID 19846612 DOI: 10.1210/en.2009-0086 |
0.075 |
|
| 2023 |
Callaghan J, Dudenhausen J, Paulson L, Hellmeyer L, Vetter K, Ziegert M, Braun T, Koenigbauer JT. Analysis of maternal mortality in Berlin, Germany - discrepancy between reported maternal mortality and comprehensive death certificate exploration. Journal of Perinatal Medicine. PMID 38109281 DOI: 10.1515/jpm-2023-0403 |
0.073 |
|
| 2013 |
Braun T, Challis JR, Newnham JP, Sloboda DM. Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk. Endocrine Reviews. 34: 885-916. PMID 23970762 DOI: 10.1210/er.2013-1012 |
0.072 |
|
| 2007 |
Braun T, Li S, Moss TJ, Newnham JP, Challis JR, Gluckman PD, Sloboda DM. Maternal betamethasone administration reduces binucleate cell number and placental lactogen in sheep. The Journal of Endocrinology. 194: 337-47. PMID 17641283 DOI: 10.1677/JOE-07-0123 |
0.07 |
|
| 2020 |
Schwickert A, Chantraine F, Ehrlich L, Henrich W, Muallem MZ, Nonnenmacher A, Petit P, Weizsäcker K, Braun T. Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study. Reproductive Sciences (Thousand Oaks, Calif.). PMID 33025531 DOI: 10.1007/s43032-020-00319-y |
0.068 |
|
| 2015 |
Justus G, Sloboda DM, Henrich W, Plagemann A, Dudenhausen JW, Braun T. Avoiding the prenatal programming effects of glucocorticoids: are there alternative treatments for the induction of antenatal lung maturation? Journal of Perinatal Medicine. 43: 503-23. PMID 25405717 DOI: 10.1515/jpm-2014-0295 |
0.068 |
|
| 2013 |
Chantraine F, Braun T, Gonser M, Henrich W, Tutschek B. Prenatal diagnosis of abnormally invasive placenta reduces maternal peripartum hemorrhage and morbidity. Acta Obstetricia Et Gynecologica Scandinavica. 92: 439-44. PMID 23331024 DOI: 10.1111/aogs.12081 |
0.065 |
|
| 2018 |
Braun T, Weizsäcker K, Muallem MZ, Tillinger J, Hinkson L, Chantraine F, Henrich W. Abnormally invasive placenta (AIP): pre-cesarean amnion drainage to facilitate exteriorization of the gravid uterus through a transverse skin incision. Journal of Perinatal Medicine. PMID 29870394 DOI: 10.1515/jpm-2017-0388 |
0.064 |
|
| 2015 |
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Chalumeau NC, Kahn J, Hamidou M, Park S, Puechal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, et al. 35 SYSTEMIC INFLAMMATORY AND AUTOIMMUNE DISEASES (SAID) ASSOCIATED WITH MDS: A FRENCH MULTICENTER RETROSPECTIVE STUDY Leukemia Research. 39: S15-S16. DOI: 10.1016/S0145-2126(15)30036-9 |
0.063 |
|
| 2021 |
Braun T, Ehrlich L, Henrich W, Koeppel S, Lomako I, Schwabl P, Liebmann B. Detection of Microplastic in Human Placenta and Meconium in a Clinical Setting. Pharmaceutics. 13. PMID 34206212 DOI: 10.3390/pharmaceutics13070921 |
0.061 |
|
| 2018 |
Seidel V, Braun T, Weizsäcker K, Henrich W. Application of chitosan-covered gauze in combination with intrauterine balloon tamponade for postpartum hemorrhage treatment - Case report of a novel "uterine sandwich" approach. International Journal of Surgery Case Reports. 48: 101-103. PMID 29883918 DOI: 10.1016/j.ijscr.2018.05.006 |
0.056 |
|
| 2022 |
Enste R, Cricchio P, Dewandre PY, Braun T, Leonards CO, Niggemann P, Spies C, Henrich W, Kaufner L. Placenta accreta spectrum part I: anesthesia considerations based on an extended review of the literature. Journal of Perinatal Medicine. PMID 36181730 DOI: 10.1515/jpm-2022-0232 |
0.055 |
|
| 2021 |
Morlando M, Schwickert A, Stefanovic V, Gziri MM, Pateisky P, Chalubinski KM, Nonnenmacher A, Morel O, Braun T, Bertholdt C, Van Beekhuizen HJ, Collins SL. Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study. Acta Obstetricia Et Gynecologica Scandinavica. PMID 33713033 DOI: 10.1111/aogs.14120 |
0.055 |
|
| 2023 |
Kennedy KM, de Goffau MC, Perez-Muñoz ME, Arrieta MC, Bäckhed F, Bork P, Braun T, Bushman FD, Dore J, de Vos WM, Earl AM, Eisen JA, Elovitz MA, Ganal-Vonarburg SC, Gänzle MG, et al. Questioning the fetal microbiome illustrates pitfalls of low-biomass microbial studies. Nature. 613: 639-649. PMID 36697862 DOI: 10.1038/s41586-022-05546-8 |
0.054 |
|
| 2022 |
Rammaert B, Maunoury C, Rabeony T, Correas JM, Elie C, Alfandari S, Berger P, Rubio MT, Braun T, Bakouboula P, Candon S, Montravers F, Lortholary O. Does F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis? Frontiers in Medicine. 9: 1026067. PMID 36606049 DOI: 10.3389/fmed.2022.1026067 |
0.054 |
|
| 2012 |
Li S, Nitsos I, Polglase GR, Braun T, Moss TJ, Newnham JP, Challis JR. The effects of dexamethasone treatment in early gestation on hypothalamic-pituitary-adrenal responses and gene expression at 7 months of postnatal age in sheep. Reproductive Sciences (Thousand Oaks, Calif.). 19: 260-70. PMID 22101239 DOI: 10.1177/1933719111418374 |
0.053 |
|
| 2022 |
Biele C, Radtke L, Kaufner L, Hinkson L, Braun T, Henrich W, Dückelmann AM. Does the use of chitosan covered gauze for postpartum hemorrhage reduce the need for surgical therapy including hysterectomy? A databased historical cohort study. Journal of Perinatal Medicine. PMID 35611816 DOI: 10.1515/jpm-2021-0533 |
0.052 |
|
| 2019 |
Dueckelmann AM, Hinkson L, Nonnenmacher A, Siedentopf JP, Schoenborn I, Weizsaecker K, Kaufner L, Henrich W, Braun T. Uterine packing with chitosan-covered gauze compared to balloon tamponade for managing postpartum hemorrhage. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 240: 151-155. PMID 31284089 DOI: 10.1016/j.ejogrb.2019.06.003 |
0.052 |
|
| 2019 |
Collins SL, Alemdar B, van Beekhuizen HJ, Bertholdt C, Braun T, Calda P, Delorme P, Duvekot JJ, Gronbeck L, Kayem G, Langhoff-Roos J, Marcellin L, Martinelli P, Morel O, Mhallem M, et al. Evidence-based guidelines for the management of abnormally-invasive placenta (AIP): recommendations from the International Society for AIP. American Journal of Obstetrics and Gynecology. PMID 30849356 DOI: 10.1016/j.ajog.2019.02.054 |
0.051 |
|
| 2021 |
Lazarides C, Moog NK, Verner G, Voelkle MC, Henrich W, Heim CM, Braun T, Wadhwa PD, Buss C, Entringer S. The association between history of prenatal loss and maternal psychological state in a subsequent pregnancy: an ecological momentary assessment (EMA) study. Psychological Medicine. 1-11. PMID 34127159 DOI: 10.1017/S0033291721002221 |
0.05 |
|
| 2021 |
Hinkson L, Dame C, Braun T, Nachtigall I, Henrich W. Response to Letter to the editor on: "Never too late? Quadruplets at the age of 65 years". Archives of Gynecology and Obstetrics. PMID 34757455 DOI: 10.1007/s00404-021-06256-8 |
0.05 |
|
| 2013 |
Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, et al. OP0145 Induction therapy with adalimumab plus methotrexate versus methotrexate monotherapy in recent onset rheumatoid arthritis (RA) – an investigator initiated randomized controlled trial: Annals of the Rheumatic Diseases. 71: 102.2-103. DOI: 10.1136/annrheumdis-2012-eular.1828 |
0.049 |
|
| 2022 |
Paping A, Basler C, C Rancourt R, Ehrlich L, Melchior K, Henrich W, Braun T. Optimized RNA isolation of FFPE uterine scar tissues for RNA expression analyses delineated by laser microdissection. Biotechniques. 72: 273-278. PMID 35546498 DOI: 10.2144/btn-2022-0026 |
0.048 |
|
| 2016 |
Weichert A, Braun T, Deutinger C, Henrich W, Kalache KD, Neymeyer J. Prenatal decision-making in the second and third trimester in trisomy 21-affected pregnancies. Journal of Perinatal Medicine. PMID 27442357 DOI: 10.1515/jpm-2016-0108 |
0.047 |
|
| 2021 |
Czamara D, Dieckmann L, Röh S, Kraemer S, Rancourt RC, Sammallahti S, Kajantie E, Laivuori H, Eriksson JG, Räikkönen K, Henrich W, Plagemann A, Binder EB, Braun T, Entringer S. Betamethasone administration during pregnancy is associated with placental epigenetic changes with implications for inflammation. Clinical Epigenetics. 13: 165. PMID 34446099 DOI: 10.1186/s13148-021-01153-y |
0.046 |
|
| 2022 |
Enste R, Cricchio P, Dewandre PY, Braun T, Leonards CO, Niggemann P, Spies C, Henrich W, Kaufner L. Placenta Accreta Spectrum Part II: hemostatic considerations based on an extended review of the literature. Journal of Perinatal Medicine. PMID 36181735 DOI: 10.1515/jpm-2022-0233 |
0.046 |
|
| 2021 |
Kennedy KM, Gerlach MJ, Adam T, Heimesaat MM, Rossi L, Surette MG, Sloboda DM, Braun T. Fetal meconium does not have a detectable microbiota before birth. Nature Microbiology. PMID 33972766 DOI: 10.1038/s41564-021-00904-0 |
0.043 |
|
| 2021 |
Morel O, van Beekhuizen HJ, Braun T, Collins S, Pateisky P, Calda P, Henrich W, Al Naimi A, Nikoline Norgaardt L, Chalubinski KM, Sentilhes L, Tutschek B, Schwickert A, Stefanovic V, Bertholdt C, et al. Performance of antenatal imaging to predict placenta accreta spectrum degree of severity. Acta Obstetricia Et Gynecologica Scandinavica. 100: 21-28. PMID 33811333 DOI: 10.1111/aogs.14112 |
0.042 |
|
| 2021 |
Vieira MC, Rijken MJ, Braun T, Chantraine F, Morel O, Schwickert A, Stefanovic V, van Beekhuizen H, Collins SL. The relation between maternal obesity and placenta accreta spectrum: A multinational database study. Acta Obstetricia Et Gynecologica Scandinavica. 100: 50-57. PMID 33811335 DOI: 10.1111/aogs.14075 |
0.04 |
|
| 2021 |
Braun T, Filleböck V, Metze B, Bührer C, Plagemann A, Henrich W. Dosage escalation of antenatal steroids in preterm twin pregnancies does not improve long-term outcome. Journal of Perinatal Medicine. PMID 34252994 DOI: 10.1515/jpm-2020-0575 |
0.037 |
|
| 2021 |
Braun T, van Beekhuizen HJ, Morlando M, Morel O, Stefanovic V. Developing a database for multicenter evaluation of placenta accreta spectrum. Acta Obstetricia Et Gynecologica Scandinavica. 100: 7-11. PMID 33811336 DOI: 10.1111/aogs.14085 |
0.034 |
|
| 2015 |
Braun T, Sloboda DM, Tutschek B, Harder T, Challis JR, Dudenhausen JW, Plagemann A, Henrich W. Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 130: 64-9. PMID 25872453 DOI: 10.1016/j.ijgo.2015.01.013 |
0.03 |
|
| 2021 |
Hinkson L, Dame C, Braun T, Nachtigall I, Henrich W. Never too late? Quadruplets at the age of 65 years. Archives of Gynecology and Obstetrics. PMID 34146145 DOI: 10.1007/s00404-021-06127-2 |
0.028 |
|
| 2023 |
Hardt AK, Braun Tavares F, Ehrlich L, Henrich W, Plagemann A, Braun T. Alterations of materno-placento-fetal glucose homeostasis after a single course of antenatal betamethasone. Placenta. 142: 64-74. PMID 37651851 DOI: 10.1016/j.placenta.2023.07.295 |
0.028 |
|
| 2016 |
Braun T, Weichert A, Gil HC, Sloboda DM, Tutschek B, Harder T, Dudenhausen JW, Plagemann A, Henrich W. Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration in twin pregnancies. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 134: 329-35. PMID 27365289 DOI: 10.1016/j.ijgo.2016.02.016 |
0.028 |
|
| 2023 |
Kennedy KM, Plagemann A, Sommer J, Hofmann M, Henrich W, Barrett JFR, Surette MG, Atkinson S, Braun T, Sloboda DM. Parity modulates impact of BMI and gestational weight gain on gut microbiota in human pregnancy. Gut Microbes. 15: 2259316. PMID 37811749 DOI: 10.1080/19490976.2023.2259316 |
0.026 |
|
| 2021 |
van Beekhuizen HJ, Stefanovic V, Schwickert A, Henrich W, Fox KA, MHallem Gziri M, Sentilhes L, Gronbeck L, Chantraine F, Morel O, Bertholdt C, Braun T, Rijken MJ, Duvekot JJ, International Society Of Placenta Accreta Spectrum Is-Pas Group T. A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum. Acta Obstetricia Et Gynecologica Scandinavica. PMID 33483943 DOI: 10.1111/aogs.14096 |
0.025 |
|
| 2017 |
Muallem MZ, Henrich W, Braun T, Sehouli J, Kretzschmar L. Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review. Anticancer Research. 37: 2487-2490. PMID 28476817 DOI: 10.21873/anticanres.11589 |
0.024 |
|
| 2018 |
Schwickert A, Wolfgang Henrich W, Braun T. Uterine scar thickness as an important outcome for the evaluation of up-to-date uterine closure techniques. American Journal of Obstetrics and Gynecology. PMID 30144400 DOI: 10.1016/j.ajog.2018.08.024 |
0.019 |
|
| 2012 |
Chantraine F, Blacher S, Berndt S, Palacios-Jaraquemada J, Sarioglu N, Nisolle M, Braun T, Munaut C, Foidart JM. Abnormal vascular architecture at the placental-maternal interface in placenta increta. American Journal of Obstetrics and Gynecology. 207: 188.e1-9. PMID 22939721 DOI: 10.1016/j.ajog.2012.06.083 |
0.015 |
|
| 2008 |
Fain O, Morin AS, Braun T, Agranat P, Stirnemann J. [Chylous ascites]. La Revue Du Praticien. 58: 1641. PMID 19044045 |
0.014 |
|
| 2022 |
Paping A, Basler C, Melchior K, Ehrlich L, Thiele M, Duda GN, Henrich W, Braun T. Intraoperative ultrasound during repeat cesarean delivery facilitates sampling of uterine scar tissue. Journal of Perinatal Medicine. 51: 87-96. PMID 36394552 DOI: 10.1515/jpm-2022-0334 |
0.013 |
|
| 2023 |
Romero R, Jahnke H, Braun T, Chervenak F, D'Addario V, Ellington M, Genc MR, Greenough A, Grunebaum A, Kurjak A, Skupski DW, Zalud I. A Celebration of Professor Joachim Dudenhausen. Journal of Perinatal Medicine. 51: 285-290. PMID 36848396 DOI: 10.1515/jpm-2023-2001 |
0.01 |
|
| 2021 |
Kaps C, Schwickert A, Dimitrova D, Nonnenmacher A, Siedentopf JP, Henrich W, Braun T. Online survey on uterotomy closure techniques in caesarean section. Journal of Perinatal Medicine. PMID 34229368 DOI: 10.1515/jpm-2021-0118 |
0.01 |
|
| Hide low-probability matches. |